Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

Haematologica

Volumn 95, Issue 3, 2010, Pages 382-387

  Sloand, Elaine M ^a   Olnes, Matthew J ^a   Weinstein, Barbara ^a   Wu, Colin ^a   Maciejewski, Jaroslaw ^a   Scheinberg, Phillip ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Immunosuppression; Interleukin 2 receptors; Marrow failure; T regulatory cells

Indexed keywords

CORTICOSTEROID DERIVATIVE; DACLIZUMAB; PREDNISONE;

APLASTIC ANEMIA; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PURE RED CELL ANEMIA; SURVIVAL RATE; TREATMENT RESPONSE;

ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; RED-CELL APLASIA, PURE; SAFETY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949707207     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013557     Document Type: Article

References (28)

1. Young NS, Tisdale JF. High-dose cyclophosphamide for treatment of aplastic anemia. Ann Intern Med. 2002;137(6):549-50.
2. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidneygraft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351(9103):623-8.
3. Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008; 93(10):1555-9.
4. Shimamoto T, Tohyama K, Okamoto T, Uchiyama T, Mori H, Tomonaga M, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res. 2003; 27(9): 783-8.
5. Mor E, Yussim A, Chodoff L, Schwartz ME. New immunosuppressive agents for maintenance therapy in organ transplantation. BioDrugs. 1997;8(6):469-88.
6. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9): 1130-5.
7. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102(10): 3584-6.
8. Sloand EM, Scheinberg P, Maciejewski J, Young NS. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab). Ann Intern Med. 2006; 144(3):181-5.
9. Waldmann TA, Levy R, Coller BS. Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program. 2000:394-408.
10. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Phase III Daclizumab Study Group. Transplantation. 2001; 72(5):839-45.
11. Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation. 2002;73(7): 1100-6.
12. Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, et al. High-dose humanized anti-IL-2 receptor a antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008; 31(2):91-7.
13. Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Daclizumab in treatment of multiple sclerosis patients. Mult Scler. 2009; 15(2):272-4.
14. Kim SE. Daclizumab treatment for multiple sclerosis. Pharmacotherapy. 2009;29(2): 227-35.
15. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338(3): 161-5.
16. Maciejewski JP, Risitano AM, Sloand EM, Wisch L, Geller N, Barrett JA, et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol. 2002; 117(1):119-26.
17. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005; 23(12):2805-12.
18. Koon HB, Severy P, Hagg DS, Butler K, Hill T, Jones AG, et al. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res. 2006;30(2):190-203.
19. Gabler C, Blank N, Hieronymus T, Schiller M, Berden JH, Kalden JR, et al. Extranuclear detection of histones and nucleosomes in activated human lymphoblasts as an early event in apoptosis. Ann Rheum Dis. 2004; 63(9):1135-44.
20. Tkaczuk J, Yu CL, Baksh S, Milford EL, Carpenter CB, Burakoff SJ, et al. Effect of anti-IL-2Ra antibody on IL-2-induced Jak/STAT signaling. Am J Transplant. 2002(1);2:31-40.
21. Snyder JT, Shen J, Azmi H, Hou J, Fowler DH, Ragheb JA. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 2007;109(12): 5399-406.
22. Wang Z, Xiao L, Shi BY, Qian YY, Bai HW, Chang JY, et al. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4+CD25 high regulatory T cells in kidney transplantation. Transplant Immunol. 2008;19(1):69-73.
23. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723-35.
24. Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transplant Immunol. 2007; 18(1):13-21.
25. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant. 2003;3(1):50-2.
26. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. Daclizumab, a humanized anti-interleukin-2 receptor a chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95(1):83-9.
27. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-{b} induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875-86.
28. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant. 2007;40(5):481-6.